A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer

NCT07740720 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms, Rectal

Interventions

BIOLOGICAL: Dostarlimab

Sponsor

GlaxoSmithKline